CPC A61K 31/232 (2013.01) [A61K 31/202 (2013.01); A61K 31/355 (2013.01); A61K 45/06 (2013.01); A61P 3/06 (2018.01); A61P 9/12 (2018.01); A61P 9/14 (2018.01); A61K 9/4875 (2013.01)] | 20 Claims |
1. A method of reducing risk of arterial plaque development in a subject on statin therapy, the method comprising administering to the subject about 4 g of ethyl icosapentate per day, wherein:
the subject has fasting baseline triglyceride levels between about 200 mg/dl to about 500 mg/dl, and
the ethyl icosapentate is present in a pharmaceutical composition and the ethyl icosapentate comprises at least about 96 wt. % of all omega-3 fatty acids in the pharmaceutical composition, wherein:
the pharmaceutical composition further comprises about 0.1% to about 4%, by weight, of total fatty acids other than EPA and/or DHA, wherein the total fatty acid other than EPA and/or DHA comprises at least one selected from the group consisting of octadecatetraenoic acid (ODTA) or an ethyl ester thereof, nonaecapentaenoic acid (NDPA) or an ethyl ester thereof, eicosatetraenoic acid (ETA) or an ethyl ester thereof, and heneicosapentaenoic (HPA) or an ethyl ester thereof, and
the pharmaceutical composition comprises substantially no docosahexaenoic acid (DHA) or an ethyl ester thereof.
|